Why These 15 Stocks Are Skyrocketing in 2025

Page 14 of 14

1. Intra-Cellular Therapies (NASDAQ:ITCI)

Number of Hedge Fund Holders In Q3 2024: 44

Intra-Cellular Therapies (NASDAQ:ITCI) is a biopharma company that makes small-molecule drugs. These drugs are mostly for CNS conditions, and the main product here is already approved in the U.S. for schizophrenia and depressive episodes linked to bipolar disorder.

The stock rose sharply in 2025 after Johnson & Johnson announced that it would acquire Intra-Cellular Therapies for $14.6 billion in cash at $132 per share.

Intra-Cellular Therapies continued to post strong gains in Caplyta sales. In its Q3 2024 report, the company recorded net product sales of $175.2 million, up 39% from the same quarter in 2023. Total quarterly revenues were $175.4 million, and the net loss was $26.3 million.

In addition, management has their 2024 sales guidance at $655 million to $685 million and says the company has more than $1 billion in “cash, cash equivalents, investment securities, and restricted cash.”

The average analyst price target for ITCI is $120.9, which implies 5% downside.

ITCI stock is up 51.2% year-to-date.

While we acknowledge the potential of ITCI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ITCI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 10 Hottest Mid-Cap Stocks So Far in 2025 and 10 Hottest Smid-Cap Stocks So Far In 2025

Disclosure: None. This article was originally published at Insider Monkey.

Page 14 of 14